Jason Fontenot
Plus aucun poste en cours
Fortune : 68 544 $ au 30/04/2024
Profil
Jason D.
Fontenot worked as the Chief Scientific Officer & Senior Vice President at Sangamo Therapeutics, Inc. from 2021 to 2024.
Prior to that, he was the Chief Scientific Officer at Immusoft Corp.
from 2018 to 2019 and the Head-Exploratory Research at Juno Therapeutics, Inc. from 2016 to 2018.
He earned a doctorate degree from the University of Washington.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/11/2023 | 136 270 ( 0,07% ) | 68 544 $ | 30/04/2024 |
Anciens postes connus de Jason Fontenot
| Sociétés | Poste | Fin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 02/01/2024 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | 01/03/2019 |
| JUNO THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | 01/01/2018 |
Formation de Jason Fontenot
| University of Washington | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |